Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**11C-meta-hydroxyephedrine** is a radiolabeled catecholamine analog used as a positron emission tomography (PET) imaging agent for the sympathetic nervous system. Labeled with carbon-11, it enables visualization and quantification of presynaptic sympathetic nerve terminals, particularly in the heart. The compound acts as an analog of norepinephrine and is taken up by norepinephrine reuptake transporters (NET), providing a measure of neuronal integrity and function. It is resistant to metabolism by monoamine oxidase and catechol-O-methyltransferase, allowing for high retention in target tissues. Its primary clinical applications are in cardiac PET imaging to assess sympathetic innervation, but it has also been studied for use in evaluating tumors of the sympathetic nervous system and other conditions involving autonomic dysfunction[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 11C-meta-hydroxyephedrine.